{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown","Transcriptomics","Genomics","Proteomics"],"submitter":["Shilpee Dutt"],"instrument_platform":["Illumina NovaSeq 6000"],"study_type":["RNA-seq of coding RNA"],"organism":["Homo sapiens"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-14162"],"description":["Glioblastoma (GBM) is a malignant grade IV brain tumor, and despite the multimodal therapeutic approaches, which include surgery and chemo-radiotherapy, recurrence is inevitable, arising from therapy-resistant residual cells. To study the residual population's survival mechanism(s), we established a radiation survival model from GBM cells and primary patient cultures (parent or P). Interestingly, the residual cells (RS), although non-proliferative and enriched in multinucleated and giant cell phenotype (MNGCs) phenotype, underwent unconventional cell division (end of residual or ERS phase) in the absence of spindle structures and cytokinesis to generate aggressive relapse (R). RNA sequencing of GBM cell line U87MG and patient sample 2 (PS2) at different time points post-radiation treatment was performed to understand the molecular players behind this residual cell division."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Library Construction - TruSeq RNA library protocol (Illumina) was used for generation of libraries. Post QC verification, 4 μg of intact total RNA was used for mRNA purification through oligodT beads, and library preparation was carried out according to manufacturer’s guidelines using the TruSeq RNA Sample Preparation Kit (Illumina).","Sample Collection - GBM cells (P) were grown to 70-80% confluency and subjected to their respective lethal doses of radiation U87MG (10Gy) and PS2 (14Gy). After an initial death phase, a transiently non-proliferative residual population (RS) was conformed microscopically and by monitoring cell proliferation by trypan blue method. The residual cells which resumed proliferation were designated as end of residual (ERS). Cell population after complete recovery was designated as relapse (R).","Sequencing - At least 60 million paired end reads (per sample) were generated after sequencing.","Nucleic Acid Extraction - RNA Isoplus (Takara) was used for isolation and enrichment of total RNA from parent, residual, end of residual and relapse GBM samples."],"figure_sub":["Organization","MINSEQE Score","Assays and Data","MAGE-TAB Files"],"pubmed_authors":["Shilpee Dutt"],"additional_accession":[]},"is_claimable":false,"name":"RNA-seq of U87MG and patient sample 2 (PS2) at different time points post-radiation treatment","description":"Glioblastoma (GBM) is a malignant grade IV brain tumor, and despite the multimodal therapeutic approaches, which include surgery and chemo-radiotherapy, recurrence is inevitable, arising from therapy-resistant residual cells. To study the residual population's survival mechanism(s), we established a radiation survival model from GBM cells and primary patient cultures (parent or P). Interestingly, the residual cells (RS), although non-proliferative and enriched in multinucleated and giant cell phenotype (MNGCs) phenotype, underwent unconventional cell division (end of residual or ERS phase) in the absence of spindle structures and cytokinesis to generate aggressive relapse (R). RNA sequencing of GBM cell line U87MG and patient sample 2 (PS2) at different time points post-radiation treatment was performed to understand the molecular players behind this residual cell division.","dates":{"release":"2025-08-15T00:00:00Z","modification":"2024-06-07T10:50:28.787Z","creation":"2024-06-07T10:50:28.787Z"},"accession":"E-MTAB-14162","cross_references":{"ENA":["ERP160960"],"EFO":["EFO_0002944","EFO_0004170","EFO_0005518","EFO_0003738","EFO_0004184"]}}